← 返回

衰老的人类成纤维细胞 FasL 表达增加,并损害肿瘤免疫反应

英文原题:Senescent human fibroblasts have increased FasL expression and impair the tumor immune response.

查看英文原题

Senescent human fibroblasts have increased FasL expression and impair the tumor immune response.

PubMed 2025/10/27(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

我们的结果确定了 FasL 表达是衰老肿瘤微环境的一个新组成部分,并强调了在人源化模型中评估治疗诱导衰老影响的重要性,以理解和预测癌症治疗的结果。

研究思路结论见上方概要

同基因小鼠肿瘤模型已表明,衰老以多种方式影响肿瘤免疫反应,包括诱导免疫抑制微环境或促进免疫细胞募集。然而,衰老在人源化背景下对肿瘤免疫反应的影响在很大程度上仍未被探索。

为了解决这个问题,我们采用了细胞共培养模型、肿瘤球体以及携带对来自同一供体的人类免疫细胞具有免疫原性的肿瘤的小鼠。

我们发现,衰老成纤维细胞通过增强免疫细胞向肿瘤微环境的募集,同时促进T细胞和NK细胞凋亡,发挥双重作用。在机制上,我们证明这种凋亡主要归因于衰老成纤维细胞表面Fas配体(FasL)表达的升高。在不同的人类成纤维细胞系中,响应不同的衰老诱导剂均观察到FasL表达升高,其中对RAS诱导的衰老反应尤为显著。在小鼠中,敲除成纤维细胞上的FasL足以防止免疫细胞死亡并增强对肿瘤细胞的杀伤。

展开英文摘要原文

To address this question, we employed a combination cells co-culture models, tumor spheroids and mice bearing tumors immunogenic to human immune cells derived from the same donor.

We found that senescent fibroblasts exert a dual effect by enhancing the recruitment of immune cells into the tumor microenvironment while simultaneously promoting the apoptosis of T and NK cells. Mechanistically, we demonstrate that this apoptosis is primarily due to increased Fas ligand (FasL) expression on the surface of senescent fibroblasts. Increased FasL expression was observed on different human fibroblast cell lines in response to different senescence inducers with a particular robust effect in response to RAS-induced senescence. Deletion of FasL on fibroblasts was sufficient to prevent immune cell death and increase tumor cell killing in mice. DISCUSSION: Our results identified the expression of FasL expression as a novel component of the senescent tumor microenvironment and highlight the importance of evaluating the impact of therapy-induced senescence in humanized models to understand and predict the outcome of cancer treatments.

论文信息

作者
Cruz-Barrera M、Dulong J、Mansour Nehmo G、Sonn A、Moquin-Beaudry G、Benabdallah B、Le O、Beauséjour C
单位
Centre de Recherche du Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montréal, QC, Canada.Canada
期刊
Frontiers in immunology2025
原文标识
PubMed 41221280 · DOI 10.3389/fimmu.2025.1685269